Business
Pharmaceutical Firms Scale Back UK Investments Amid Drug Pricing Disputes
Multinational drugmakers are pausing or pulling back investments in the United Kingdom, citing concerns over uncompetitive drug pricing and strained relations with the government. The slowdown comes as Britain seeks to position itself as a hub for life sciences, a sector the government has long promoted as central to its post-Brexit economic strategy.
Eli Lilly, AstraZeneca, and Merck are among the companies that have recently scaled back or halted projects in the UK. Earlier this month, AstraZeneca suspended a planned £200 million expansion of its Cambridge research site, following the cancellation of a vaccine project in Liverpool. Merck, known in Europe as MSD, said it would relocate its London research operations to the United States. Meanwhile, Eli Lilly has paused its £279 million London Gateway Lab, saying it was awaiting “more clarity around the UK life sciences environment.”
The moves follow sharp criticism from Eli Lilly’s chief executive Dave Ricks, who last week told the Financial Times that Britain was “probably the worst country in Europe” for drug pricing. His remarks have further highlighted growing friction between the pharmaceutical industry and the government.
Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), urged ministers to act. “We have a long and proud history of researching and manufacturing medicines in this country,” he said. “This is why we urge the government to improve how this country values and attracts future life sciences manufacturing.”
The UK spends a smaller share of its health budget on medicines than most developed nations — around 9% compared with 14–20% elsewhere. Much of this is due to the NHS’s heavy use of generic drugs and the role of the National Institute for Health and Care Excellence (NICE), which determines whether branded medicines are cost-effective. In addition, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) caps NHS spending on branded medicines, requiring firms to pay back revenue when expenditure exceeds agreed limits. Companies argue the rebates have become unsustainable.
Adding to the pressure, new U.S. trade policies are reshaping the global market. President Donald Trump recently announced 100% tariffs on branded drug imports unless firms build plants in the U.S., alongside a “most favoured nation” pricing policy that could ripple across Europe. With the U.S. accounting for roughly 70% of global pharma profits, analysts say many companies are prioritising American operations over European ones.
Experts note that higher UK drug prices are not necessarily the solution. Irene Papanicolas, director at the Brown University School of Public Health, argued that if pharma firms retreat, “the bigger impact is on the economy and jobs” rather than patient access to medicines. Beth Woods, senior research fellow at the University of York, added: “Our research supports more stringent price regulation in the UK. More investment could fund screening programmes, hip replacements, or staffing increases.”
Analysts say that beyond pricing, the UK must strengthen its tax incentives, infrastructure, and research funding to remain attractive. Without decisive action, they warn, Britain risks losing ground in the global competition for pharmaceutical investment.
Business
Global Markets Rise as US–Iran Talks Ease Sentiment, but Oil and Geopolitical Risks Persist
Global financial markets advanced on Friday as investors reacted cautiously to signs of progress in US–Iran negotiations, though ongoing disruption to shipping through the Strait of Hormuz and elevated oil prices kept risk sentiment fragile.
European equities opened higher across the board. The DAX gained 0.64%, supported by a 3.61% rise in Deutsche Post AG shares. France’s CAC 40 climbed 0.65%, led by a 3.43% jump in STMicroelectronics. In London, the FTSE 100 rose 0.38%, with gains in financial stocks including 3i Group, while the Euro Stoxx 50 added 0.88%.
Currency markets were relatively steady, with the euro trading at $1.161 and the British pound at $1.342 in early European trading. Sentiment was also lifted by better-than-expected economic data from Germany, where first-quarter growth came in at 0.4% year on year and consumer confidence improved heading into June, offering cautious optimism for Europe’s largest economy.
Asian markets followed the upward trend. Japan’s Nikkei 225 surged 2.7% to 63,339 after data showed inflation easing to a four-year low of 1.4% in April. Taiwan’s Taiex rose 2.2%, while Hong Kong’s Hang Seng and China’s Shanghai Composite each gained 0.9%. South Korea, Australia, and India also posted modest increases, reflecting broad regional strength.
Wall Street had earlier closed slightly higher. The S&P 500 added 0.2%, the Dow Jones rose 0.6%, and the Nasdaq edged up 0.1%. However, technology stocks showed mixed signals, with Nvidia falling 1.8% despite strong quarterly results, as investors weighed valuations against broader market uncertainty.
Oil markets remained the key source of volatility. Brent crude climbed 2.3% to $104.97 a barrel, while US West Texas Intermediate rose 1.8% to $98.10. Prices remain significantly above pre-conflict levels, driven by continued disruption in the Strait of Hormuz, through which roughly a quarter of global seaborne oil flows pass.
Shipping through the strategic waterway remains constrained, with limited signs of recovery as diplomatic negotiations continue without resolution. Analysts say markets are highly sensitive to developments in talks between Washington and Tehran, with ING commodities strategists noting that optimism exists but uncertainty dominates trading conditions.
Geopolitical tensions also weighed on policy discussions in Washington, where a planned congressional vote on war powers legislation was postponed amid insufficient support.
In bond markets, US Treasury yields eased slightly to 4.57% after earlier spikes driven by inflation concerns linked to energy prices. The movement reflected ongoing caution among investors balancing growth expectations with persistent geopolitical risk.
Corporate earnings added a bright spot in Asia, where Lenovo Group surged more than 20% after reporting stronger-than-expected quarterly revenue of $21.6 billion, driven by robust performance in its PC and smart devices division.
Business
Goldman Sachs tapped to lead SpaceX IPO as Musk eyes record-breaking market debut
Business
Greek Stocks Stage Remarkable Comeback After Years of Financial Turmoil
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
